Gastrointestinal Disease News and Research

RSS

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).

12 Nov 2009

Hospitalization and death of H1N1 patients can occur at all ages, says study

In contrast with some common perceptions regarding 2009 influenza A(H1N1) infections, an examination of cases in California indicates that hospitalization and death can occur at all ages, and about 30 percent of hospitalized cases have been severe enough to require treatment in an intensive care unit, according to a study in the November 4 issue of JAMA.

4 Nov 2009

Studies highlight race- and gender-specific disparities in gastrointestinal disease

Three studies presented this week at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego underscore the growing disparities in gastrointestinal disease, particularly colon cancer and Barrett's Esophagus, among certain ethnic and gender populations, including African Americans, Latinos and women. These race- and gender-specific disparities underscore the need for education and vigilance among these populations and perhaps more aggressive screening tactics than the population in general.

27 Oct 2009

Cequent Pharmaceuticals to provide details of its clinical program at BIOCOM conference

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Chief Executive Officer, Peter Parker, will provide details on Cequent's planned launch of its clinical program and highlight strategy and development goals in a company update scheduled for 3 p.m. on Tuesday, October 27, 2009, at the 2009 BIOCOM Investor Conference.

14 Oct 2009

NiTi Surgical Solutions to showcase its investigational bowel anastomosis device at the 95th ACS Congress

NiTi™ Surgical Solutions, an innovative surgical device company, today announced that it will showcase its new, investigational bowel anastomosis device this week at the American College of Surgeons (ACS) 95th Annual Clinical Congress in Chicago, Illinois. The device, which will be marketed as BowelRing™, represents the company’s next advancement in its innovative BioDynamix™ Anastomosis Technology platform.

12 Oct 2009

Digestive Health Outcomes Registry for patients with GI disease

The American Gastroenterological Association (AGA), the leading association representing clinicians and researchers who specialize in the digestive tract, and MedAssurant, Inc., a leading provider of data-driven healthcare solutions, announced today the collaborative initiative to develop a set of registries to assist physicians, payors, policy makers, and other healthcare stakeholders in the study and improvement of clinical and quality outcomes, care management, and cost effectiveness of care delivered to Americans with gastrointestinal disease.

9 Oct 2009

New center for gastrointestinal cancer research established

Georgetown University Medical Center today announced the creation of a center that may help advance a cure for one of the deadliest forms of cancer. The Otto J. Ruesch Center for the Cure of Gastrointestinal (GI) Cancers will fund gastrointestinal cancer research, drug discovery and patient advocacy efforts at the Georgetown Lombardi Comprehensive Cancer Center.

30 Sep 2009

New understanding on how probiotics can prevent disease

Using probiotics successfully against a number of animal diseases has helped scientists from University College Cork, Ireland to understand some of the ways in which they work, which could lead to them using probiotics to prevent and even to treat human diseases.

1 Apr 2009

New vaccine developed for preventing human adenovirus type-3d virus

Common colds typically cause a week of sneezing, aches and pains and then fade away leaving only a sore nose and a few used sick days behind.

2 Feb 2009

Chimerix completes phase I study and starts phase II multi-dose trial for CMX001

Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, has announced that the Company has completed a single and multi-dose Phase I study of CMX001 in healthy volunteers.

6 Jan 2009

FDA approves Gleevec (imatinib mesylate) to prevent gastrointestinal stromal tumor

The U.S. Food and Drug Administration has approved Gleevec (imatinib mesylate) for a new indication – keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor or GIST.

21 Dec 2008

CDC MMR/autism study - wrong questions asked, wrong children studied, wrong conclusions NAA says

A Centers for Disease Control and Prevention (CDC) study released today claims there is no link between the MMR vaccine and autism. The National Autism Association (NAA) says this study does nothing to dispel the growing public concern over a vaccine-autism connection and raises several questions concerning design and methodology.

4 Sep 2008

CDC MMR/autism study - wrong questions asked, wrong children studied, wrong conclusions NAA says

4 Sep 2008

Quality of care for inflammatory bowel disease patients can be improved

Inflammatory bowel disease (IBD) is a chronic recurrent gastrointestinal disease.

26 Feb 2008

Study uncovers clues to cystic fibrosis gene dysfunction and gastrointestinal disease

A new study by researchers at Hasbro Children's Hospital, the pediatric division of Rhode Island Hospital, and Mount Sinai Hospital, New York, offers new insight into the role that the cystic fibrosis gene plays in the development of gastrointestinal disease.

14 Dec 2007

New device rapidly diagnoses gastrointestinal disease by 'reading' the odour of biological fluids

A pioneering new device that could help over four billion adults and children who suffer from infectious diarrhoea in the developing world and reduce outbreaks of diseases such as clostridium difficile (C.Diff) in UK hospital wards is the winner of this year's University of Bristol's New Enterprise Competition.

4 Jul 2007

New smart pill helps diagnose stomach problems

People with the chronic stomach condition known as gastroparesis, or slow stomach emptying, live in fear that eating will cause an episode of nausea, vomiting and abdominal pain.

24 May 2007

Discovery of chemical profiles for infectious diarrhoea

Academics from the Universities of the West of England and Bristol have found that faeces from healthy people and those with infectious diarrhoea differ significantly in their chemical composition and could be used to diagnose quickly diseases such as Clostridium difficile (C. Diff.).

22 May 2007

New method for rapid diagnosis of intestinal illnesses

Academics have found, for the first time, smells from healthy faeces and people with infectious diarrhoea differ significantly in their chemical composition and could be used to diagnose quickly diseases such as Clostridium difficile (C. Diff.).

27 Feb 2007

New Yorkers lied to in aftermath of 9/11

A new study released this week says thousands of World Trade Center responders have developed chronic and disabling illnesses that are likely to be permanent.

12 Sep 2006

Gastrointestinal Disease News and Research

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Hospitalization and death of H1N1 patients can occur at all ages, says study

Studies highlight race- and gender-specific disparities in gastrointestinal disease

Cequent Pharmaceuticals to provide details of its clinical program at BIOCOM conference

NiTi Surgical Solutions to showcase its investigational bowel anastomosis device at the 95th ACS Congress

Digestive Health Outcomes Registry for patients with GI disease

New center for gastrointestinal cancer research established

New understanding on how probiotics can prevent disease

New vaccine developed for preventing human adenovirus type-3d virus

Chimerix completes phase I study and starts phase II multi-dose trial for CMX001

FDA approves Gleevec (imatinib mesylate) to prevent gastrointestinal stromal tumor

CDC MMR/autism study - wrong questions asked, wrong children studied, wrong conclusions NAA says

CDC MMR/autism study - wrong questions asked, wrong children studied, wrong conclusions NAA says

Quality of care for inflammatory bowel disease patients can be improved

Study uncovers clues to cystic fibrosis gene dysfunction and gastrointestinal disease

New device rapidly diagnoses gastrointestinal disease by 'reading' the odour of biological fluids

New smart pill helps diagnose stomach problems

Discovery of chemical profiles for infectious diarrhoea

New method for rapid diagnosis of intestinal illnesses

New Yorkers lied to in aftermath of 9/11

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News